Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/25/2026

1. INTC
2. DECK
3. META
4. AMD
5. INFY
6. RNG
7. SPY
8. TMUS
9. UNP
10. GOOGL

Go back to Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
(NASDAQ: PHVS) Delayed: 34.17 +0.91 (2.74%)
Previous Close $33.26    52 Week High $ 
Open $33.59    52 Week Low $ 
Day High $34.38    P/E N/A 
Day Low $33.33    EPS $ 
Volume 255,708